Abstract | OBJECTIVES: METHODS: The study population consisted of 30 patients with AMI who received emergency PCI and satisfied the inclusion criteria. Levosimendan was given as a continuous infusion of 0.1 μg/kg/min for 24 h, and the remaining 10 patients received placebo treatment. The patients were observed with invasive haemodynamic monitoring and were evaluated biochemically and echocardiographically before and after the drug infusion. RESULTS: Following treatment, biochemical indices (not including creatine kinase and its MB fraction) were significantly lower in the levosimendan group than in the placebo group. Meanwhile, left-ventricular (LV) end-systolic volume, mean pulmonary arterial pressure, pulmonary capillary wedge pressure and systemic vascular resistance were significantly reduced in the levosimendan group, whereas the early-to-late diastolic velocities ratio, LV ejection fraction, cardiac index and cardiac power index were increased. Troponin I levels were reduced and fewer stunned and infarction segments were observed in the patients treated with levosimendan. CONCLUSIONS:
|
Authors | Xiushao Wu, Jing Wu, Xifu Yan, Yanzhou Zhang |
Journal | Cardiology
(Cardiology)
Vol. 128
Issue 2
Pg. 202-8
( 2014)
ISSN: 1421-9751 [Electronic] Switzerland |
PMID | 24751502
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Biomarkers
- Cardiotonic Agents
- Hydrazones
- Pyridazines
- Simendan
|
Topics |
- Biomarkers
- Cardiotonic Agents
(administration & dosage)
- Emergency Treatment
(methods)
- Female
- Hemodynamics
(drug effects)
- Humans
- Hydrazones
(administration & dosage)
- Infusions, Intravenous
- Male
- Middle Aged
- Myocardial Infarction
(blood, physiopathology, therapy)
- Myocardial Reperfusion Injury
(physiopathology, prevention & control)
- Myocardial Stunning
(blood, drug therapy)
- Percutaneous Coronary Intervention
(methods)
- Pilot Projects
- Pyridazines
(administration & dosage)
- Simendan
- Treatment Outcome
|